Wooseok Yang, Ph.D., is a biologist with over 10 years of research experience in oncology and immunotherapy. He leads the Platform Technology Evaluation group at Samsung Biologics, where he oversees the assessment and advancement of antibody-based platform technologies, bridging cutting-edge immunology and oncology research with strategic solutions for therapeutic development. Before joining Samsung Biologics, he was a researcher at the MOGAM Institute for Biomedical Research, where he contributed to the development of bsAbs and CAR-T cell therapies. He earned his PhD in immunology from Sungkyunkwan University.